Skip to main content

Available studies

  • The following is a current list of our open, cancer-related research studies at Virginia Piper Cancer Institute locations, part of Allina Health. Patients can participate in the studies at the locations listed with each study.

    Breast cancer

    • Oncothyreon ONT-380-206 Her2+ Metastatic Breast Cancer Study
      • Description: Study of ONT-380 vs placebo in combination with capecitabine + trastuzumab in metastatic HER2+ breast cancer - must have had prior taxane, trastuzumab, pertuzumab and endocrine therapy(s) +/- CDK4/6 inhibitor unless hormone tx is not indicated
      • Locations: Abbott Northwestern Hospital, Mercy Hospital – Mercy Campus and Mercy Hospital – Unity Campus
    • Seattle Genetics SGN-LIV1A Triple Negative Study
      • Description: Safety study of SGN-LIV1A for second-line treatment in patients with metastatic triple negative breast cancer as a single agent
      • Locations: Abbott Northwestern Hospital, Mercy Hospital – Mercy Campus, and Mercy Hospital – Unity Campus
      • Seattle Genetics SGN-LIV2 Triple Negative Study
        • Description: Phase 1b/2 Study of SGN-LIV1A + pembrolizumab for first-line treatment of unresectable locally-advanced or metastatic triple negative breast cancer
        • Locations: Abbott Northwestern Hospital 
      • REOPENING SOON: Immunomedics IMMU-132-05 ASCENT Triple Negative Breast Cancer
        • Description: Phase 3 study of Sacituzumab Govitecan for third-line or greater relapsed/refractory triple-negative breast cancer
        • Location: Abbott Northwestern Hospital
      • Roche WO40181 HR+ Breast Cancer Study
        • Description: Phase II RCT of venetoclax + fulvestrant vs. fulvestrant in ER+, HER2 negative metastatic breast cancer after CDK4/6 inhibitor therapy
        • Location: Abbott Northwestern Hospital 
      • Odonate ODO-TE-B301 HR+ Breast Cancer Study
        • Description: Phase 3 study of tesetaxel + reduced dose of capecitabine vs. capecitabine alone in HR+, HER2 negative, metastatic breast cancer previously treated with a taxane in (neo)adjuvant setting
        • Location: Abbott Northwestern Hospital
      • AVAILABLE FOR RURAL PATIENTS: Lally CaringGuidance Study
        • Description: Reducing distress and depressive symptoms in rural women after breast cancer diagnosis: Randomized Controlled Pilot Study
        • Locations: Abbott Northwestern Hospital, Mercy Hospital – Mercy Campus and Mercy Hospital – Unity Campus
        • Contact: Internet-based trial; contact Dr. Robin Lally at 402-559-5464.

      Colorectal cancer

      • Clinical Genomics NOVA Study
        • Description: Evaluation of Clinical Genomics Colvera test in the detection of disease recurrence in patients diagnosed with colorectal cancer
        • Location: Abbott Northwestern Hospital

      Cholangiocarcinoma

      • No available trials at this time

      Esophageal cancer

      • Takeda TAK-931-2001 Study
        • Description: Phase 2 study to evaluate TAK-931 single agent in pts with locally advanced or metastatic squamous esophageal cancer after first line tx for metastatic disease
        • Location: Abbott Northwestern Hospital

      Gastric cancer

      • No available trials at this time

      Glioblastoma

      • No available trials at this time

      Gynecology cancers (cervical and ovarian cancer)

      • AZ LIGHT Ovarian Cancer Study
        • Description: Open-label Phase II study to assess olaparib tablets for patient with different HRD tumor status, platinum-sensitive, relapsed ovarian, fallopian tube or primary peritoneal cancer that have had at least 1 prior line of chemotherapy
        • Location: TBD

      Head and neck cancer

      • Rakuten Aspyrian Recurrent Head & Neck Cancer Study
        • Description: Phase 3 randomized open-label study of ASP-1929 photoimmunotherapy vs.physician's choice SOC for locoregional, recurrent head & neck squamous cell carcinoma on or after at least 2 prior lines of therapy
        • Location: Abbott Northwestern Hospital

      Hematology

      • No available trials at this time

      Hepatobiliary cancer

      • Mayo Hepatobiliary Registry and Biorepository
        • Description: International registry of hepatobiliary cancers including hepatocellular carcinoma, cholangiocarcinoma, and gallbladder adenocarcinoma, and unaffected individuals
        • Locations: Abbott Northwestern Hospital and Mercy Hospital – Mercy Campus

      Lung cancer

      • Dynavax DV9-NSC-01 Lung Cancer Study
        • Description: Phase 1b Dose Escalation and Expansion Trial of DV281 + Anti-PD-1inhibitor in advanced Non-Small Cell Lung Cancer
        • Location: Abbott Northwestern Hospital
      • Takeda TAK-931-2001 Study
        • Description: Phase 2 study to evaluate TAK-931 single agent in patients with locally advanced or metastatic squamous lung cancer after ≥ 2 lines of tx for metastatic disease
          Location: Abbott Northwestern Hospital

      Lymphoma/Leukemia

      • Debiopharm 1562-201 NHL Study
        • Description: Phase 2 study of Debio 1562+ rituximab in relapsed/refractory DLBCL
        • Locations: Abbott Northwestern Hospital & Mercy Hospital – Mercy Campus
      • Trovagene TROV-052 AML Study
        • Description: Phase 1b/2 study of PCM-075 + low-dose cytarabine or decitabine in Acute Myeloid Leukemia
        • Locations: Abbott Northwestern Hospital
      • DeNovo DLBC Lymphoma DB102-02
        • Description: Phase 3 study of enzastaurin + R-CHOP versus R-CHOP in treatment-naïve high-risk DLBC Lymphoma with genomic biomarker DGM1
        • Locations: Abbott Northwestern Hospital and Mercy Hospital

      Melanoma

      Multiple myeloma

      • No available trials at this time

      Ovarian cancer

      Pancreatic cancer

        • COMING SOON:  Geistlich GP-2250 1001 Pancreas Cancer Study
          • Description: Phase 1/ 2 trial of GP-2250 + gemcitabine in metastatic pancreatic cancer who have progressed on FOLFIRINOX
          • Location: Abbott Northwestern Hospital
        • ARMO AM0010-301 ARTIST 1 Pancreas Cancer Study
          • Description: Randomized phase 3 study of AM0010 + FOLFOX vs. FOLFOX alone as second-line therapy for metastatic pancreatic cancer that has progress after a first-line gemcitabine-containing regimen
          • Location: Abbott Northwestern Hospital
        • University of Minnesota Tissue Procurement Study
          • Description: Development of Oncolytic Adenovirus targeting cancer stem cells: Tissue procurement study from pancreatic or esophageal cancer surgery (Kamath/Kelsey 863-8716)
          • Location: Abbott Northwestern Hospital
        • Pancreatic Screening
          • Description: Registry Study to Determine the Utility and Feasibility of a Pancreatic Cancer Screening Program for Patients at High Risk of the Disease Based on Genetics and Family History (Rossi/Kelsey 863-8551)
          • Location: Abbott Northwestern Hospital

        Renal cell cancer

        • No available trials at this time

        Solid tumor

        • No available trials at this time

        Urothelial cancer

        • Astellas Urolothelial Cancer 7465-CL-0301
          • Description: Open-label, randomized phase 3 study of Enfortumab Vedotin vs. chemotherapy in previously treated locally advanced or metastatic urothelial cancer
          • Location: Abbott Northwestern Hospital
        • EMD Serono MS201781-0031 Solid Tumor
          • Description: Phase 1b open label study of avelumab + M9241 (NHS-IL12) for patients who have progressed after ≥ 1 platinum regimen
          • Location: Abbott Northwestern Hospital
      • Contact us

        Call 612-863-8716.

        800 E. 28th St.
        Minneapolis, MN 55407

        Research program leaders